SynthesisBioMed research international2020

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.

Shu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.